Last reviewed · How we verify
Dalacin C
Dalacin C (clindamycin) inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing peptide bond formation.
Dalacin C (clindamycin) inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing peptide bond formation. Used for Bacterial infections in oral and maxillofacial surgery, Anaerobic bacterial infections, Gram-positive bacterial infections.
At a glance
| Generic name | Dalacin C |
|---|---|
| Sponsor | Oral and Maxillofacial Surgery Clinic, Poland |
| Drug class | Lincosamide antibiotic |
| Target | Bacterial 50S ribosomal subunit |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Clindamycin is a lincosamide antibiotic that binds to the bacterial 50S ribosomal subunit and inhibits transpeptidation and translocation reactions, thereby suppressing bacterial protein synthesis. This bacteriostatic action is effective against a broad spectrum of gram-positive and anaerobic bacteria, making it useful for treating infections in oral and maxillofacial surgery where anaerobic organisms are common.
Approved indications
- Bacterial infections in oral and maxillofacial surgery
- Anaerobic bacterial infections
- Gram-positive bacterial infections
Common side effects
- Diarrhea
- Nausea
- Abdominal pain
- Pseudomembranous colitis
- Rash
Key clinical trials
- Dual vs. Single-Antibiotic Impregnated Cement in Hemiarthroplasty for Femoral Neck Fracture (PHASE3)
- Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Immunoglobulin Stopping or Extension (Stop Ig) (PHASE2, PHASE3)
- Evaluation of an Educational Intervention on Antibiotics in Dental Care (NA)
- Evaluation of Efficacy and Safety Parameters of Different Antibiotics Regimens for Management of Empyema (NA)
- Clostridioides Difficile Controlled Human Infection Model (NA)
- Socket Preservation - A Randomized Clinical Implementation in a Student Setting (NA)
- Early Intravenous to Oral Antibiotic Switch in Uncomplicated Staphylococcus Aureus Bacteraemia (PHASE3)
- Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy: Immunoglobulin Stopping or Extension (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |